Tell us about you

Work Email required

Organization required

First Name required

Last Name required

Job Title required

Phone required (###) ###-####, or int ######...

City required

State/Province required

Business Information

Tell us about your organization

error messages will go here...

Looks like we’re already familiar with you!

Please press next to continue with the survey.

Looks like we’re already familiar with you!

According to your account type you are not eligible to take surveys at this time. If this is a mistake, please contact KLAS.

If you are trying to access KLAS research data and reports, an email has been sent to   with a link to login.

If the email doesn't appear in your inbox, ask your IT department to add KLASresearch.com to your company spam filter's "whitelist", and check your email's spam folder.

Membership Commitment

In exchange for giving their feedback, healthcare providers can create an account to get access to industry reports, user commentary, and real-time ratings.

By submitting your account request, you are engaged in patient care as either an employee (or contractor) of your provider organization and that you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically.

To learn more about how we process and protect your personal data, you may view our Privacy policy.

By submitting your account request, you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically. To learn more about how we process and protect your personal data, you may view our Privacy policy.

By submitting your account request, you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically.

To learn more about how we process and protect your personal data, you may view our Privacy policy.

 

To learn more about how we process and protect your personal data, you may view our Privacy policy.

 

To learn more about how we process and protect your personal data, you may view our Privacy policy.

Thank You! Your information was submitted successfully!

Next Steps - An email has been sent to . Please follow its instructions to verify your email, and login.

If the email doesn't appear in your inbox, try asking your IT department to add KLASresearch.com to your company spam filter's "whitelist", and checking your email's spam folder.

Thank You! Your information was submitted successfully!

Next Steps - A KLAS representative will contact you to discuss working with KLAS, typically within 24 to 48 hours.

If you have any further questions please contact info@klasresearch.com or 1-800-920-4109.

Surprise! Looks like we already have an account for you.

An email has been sent to blah@blah.com with a link to login.

If the email doesn't appear in your inbox, try asking your IT department to add KLASresearch.com to your company spam filter's "whitelist", and checking your email's spam folder.

Thank you !

Access info about on your dashboard or bookmark under

(Your Products / Your Organization's Products)

Zebra Medical Vision

Headquarters:

,

Sector Funding:

Go to Website

Preferences

   Bookmark

Zebra Medical Vision's Current COVID-19 Response and Solutions

The following information was supplied by the vendor and has not been validated by KLAS.

Zebra
Identify and track development of GGO lesions, offer insights into COVID-19 severity, enable quick and effective diagnosis, triage, and evaluation of patients

  • While laboratory testing has served as the first line of diagnostics during the COVID-19 crisis, these tests have limited accuracy and do not indicate the state of disease progression. CT scans have been proven to be the most accurate tool so far for screening COVID-19 (98% accuracy vs. 71% of the PCR test).
  • Zebra is working on software for a machine-learning algorithm that analyzes CT scans. That software will offer substantially higher detection rates while conducting a comparative analysis of multiple CT scan images of the same patient in order to measure the development of the virus.
  • We are leveraging a patented algorithm that Zebra developed in the past for detecting ground glass opacities (GGO), which are imaging features of COVID-19 pneumonia. The patented technology provides segmentation of predefined features in a 2D slice of a 3D anatomical image, including GGO.
  • Zebra researchers and engineers are currently using clinical data from thousands of medical images to train the AI model of the COVID-19 solution. The algorithm will be validated against confirmed COVID-19 CT scans from newly created databases around the world.
  • By identifying and tracking the development of these GGO lesions, the software will offer key insights into disease severity and enable doctors to diagnose, triage and evaluate patients swiftly and effectively.
  • We do not believe this will replace the PCR test, but it may have substantial value since deciding which suspected COVID-19 patients should be hospitalized is challenging due to the very limited resources that the public system has. The vast majority of COVID-19 patients are mild, so having this automated tool will help make critical decisions on whether or not to hospitalize based on a COVID-19 risk score driven by the analysis of the CT images.
  • The proof of concept will be available for assessment by mid-April.

Thank you !

Access info about on your dashboard or bookmark under

(Your Products / Your Organization's Products)